Long-Term Analysis Shows Boston Scientific’s Watchman Device Saves Money
An analysis of pooled five-year data from the PROTECT AF and PREVAIL trials, show left-atrial appendage closure to prevent stroke in patients with atrial fibrillation is not only cost‐effective compared to treatment with warfarin and other anticoagulant drugs, but saves money over time.
You may also be interested in...
The series C financing will support development of its CLAAS device, an alternative to anticoagulant drugs for atrial fibrillation patients.
The final follow-up data from the CAP and CAP2 registries support left-atrial appendage closure with Watchman as an alternative to long-term anticoagulation in patients with nonvalvular atrial fibrillation.
Boston Scientific Corp. posted revenue gains across its varied product categories, helped by strong performance in emerging markets.